Iván Victoria
University of Barcelona
36 Papers
67 Citations
Iván Victoria is an academic researcher from University of Barcelona. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 9, co-authored 30 publications. Previous affiliations of Iván Victoria include Harvard University.
Chat about Author
Papers
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat,Alejandro Navarro,Laia Paré,Noemi Reguart,Patricia Galván,Tomás Pascual,A. Martinez,Paolo Nuciforo,Laura Comerma,Llucia Alos,N. Pardo,Susana Cedres,Cheng Fan,Joel S. Parker,Lydia Gaba,Iván Victoria,Nuria Viñolas,Ana Vivancos,Ana Arance,Enriqueta Felip +19 more
TL;DR: The hypothesis that identification of a preexisting and stable adaptive immune response as defined by mRNA expression pattern is reproducible and sufficient to predict clinical outcome is supported, regardless of the type of cancer or the PD1 therapeutic antibody administered to patients.
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Jordi Codony-Servat,Miriam Cuatrecasas,Elena Asensio,Carla Montironi,Anna Martínez-Cardús,Mercedes Marín-Aguilera,Carlos Horndler,Eva Martinez-Balibrea,Michele Rubini,Pedro Jares,Òscar Reig,Iván Victoria,Lydia Gaba,Marta Martin-Richard,Vicente Alonso,Pilar Escudero,Carlos Fernández-Martos,Jaime Feliu,Jose Carlos Mendez,Miguel Cadena Méndez,Javier Gallego,Antonieta Salud,Federico Rojo,Antoni Castells,Aleix Prat,Rafael Rosell,Xabier García-Albéniz,Jordi Camps,Jordi Camps,Joan Maurel +29 more
TL;DR: This study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance in patients with metastatic colorectal cancer, and significantly correlated with poor overall survival in mCRC patients.
Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma
Maria Sepúlveda,Eugenia Martinez-Hernandez,Lydia Gaba,Iván Victoria,Nuria Sola-Valls,Neus Falgàs,Jordi Casanova-Molla,Francesc Graus +7 more
TL;DR: Pembrolizumab, a monoclonal antibody directed against the immune checkpoint programmed cell death‐1 receptor (PD‐1) has improved survival in patients with advanced melanoma.
20
Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
Francisco Aya,Lydia Gaba,Iván Victoria,Aranzazu Fernandez-Martinez,Mónica Tosca,Aleix Prat,Ana Arance +6 more
TL;DR: The efficacy of ipilimumab post-anti-PD-1 was similar to that described in the previous reports on ipILimumab, and no grade 4 or 5 adverse events were reported.
17
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.
Laura Vidal,Iván Victoria,Lydia Gaba,Marta Gil Martin,Mercè Brunet,Helena Colom,Marc Cortal,Mariana Gomez-Ferreria,Marc Yeste-Velasco,Antonio Perez,Jordi Rodon,Davendra Sohal,Jose M. Lizcano,Carles Domenech,Jose Alfon,Pere Gascón +15 more
TL;DR: ABTL0812 induces endoplasmic reticulum stress and blocks the Akt-mTOR axis; both actions converge to activate a robust and sustained autophagy leading to cancer cell death as mentioned in this paper.
16